Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya

Contraception. 2005 Aug;72(2):138-45. doi: 10.1016/j.contraception.2005.04.001.


Objective: We compared 12-month continuation rates, menstrual bleeding patterns and other aspects of acceptability between users of Cyclofem and users of Depo-Provera.

Methods: The life-table method was used to calculate quarterly continuation rates. In all, 360 Kenyan women were randomly assigned to one of the two contraceptives. User-satisfaction questionnaires were administered at 6 and 12 months or at discontinuation, whichever occurred first.

Results: The 1-year continuation rate was 75.4% for Depo-Provera users versus 56.5% for Cyclofem users (p<.001). Main reasons for discontinuation included difficulty making clinic visits (45.1% for Cyclofem vs. 40% for Depo-Provera), menstrual changes (14.1% vs. 12.5%) and nonmenstrual problems (15.5% vs. 12.5%). None of the Depo-Provera users and 8.5% of the Cyclofem users claimed frequency of visits as the main reason for discontinuation. In all, 70.6% of the Depo-Provera users were amenorrheic after 12 months, as were 20.8% of the Cyclofem users.

Conclusions: The 1-year continuation rate was higher for Depo-Provera than for Cyclofem. There was no important difference in discontinuation rates because of menstrual problems; the difference mainly reflected the frequency of visits required.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Contraceptive Agents, Female / administration & dosage*
  • Contraceptives, Oral, Combined / administration & dosage*
  • Drug Combinations
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives*
  • Female
  • Follow-Up Studies
  • Humans
  • Medroxyprogesterone Acetate / administration & dosage*
  • Menstruation Disturbances / chemically induced
  • Patient Satisfaction*
  • Random Allocation
  • Surveys and Questionnaires


  • Contraceptive Agents, Female
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • Estradiol
  • CycloProvera
  • Medroxyprogesterone Acetate